Publication | Closed Access

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study

Metastatic Breast CancerBreast OncologyMedicineBreast CancerCancer TreatmentPhase 2OncologyRadiation OncologyMolecular OncologyOpen-label Bevacizumab